Protocols/Clinical Trials

Active Studies

Protocol # Protocol Name Status
ACTG A5239 A Pilot Study of Therapy with Pioglitazone Prior to HCV Treatment in HIV-! And HCV Genotype 1 Infected Subjects with Insulin Resistance Who Are Prior Nonresponders to Peginterferon and RBV Enrolling
ACTG A5240 Phase II Study to Evaluate the Immunogenicity and Safety of Gardasil in HIV-1-Infected Females with a HIV RNA>10,000 or CD4 count <200 and HIV RNA<10,000 Enrolling
ACTG A5241 Open label Phase III Trial for subjects failing their Current regime with a Viral Load >1000 and Treatment Experience with NRTI’s, NNRTI’s and PI’s.  Subjects will be randomized to add NRTI’s or not add NRTI’s to a new effective regime using the cPSS. Enrolling
ACTG A5247 Phase II study to Evaluate the Safety, Tolerability And Immunogenicity of ZOSTAVAX in Subjects with A CD4 count of 200-349 and an Undetectable Viral Load Enrolling
ACTG A5252 Phase II Study for the Treatment of HIV-Associated Painful Peripheral Neuropathy in a Double Blind, Placebo Controlled study of Duloxetine and methadone Enrolling
ACTG A5257 Phase III Comparative Study of Three NNRTI Sparing ART’s for Treatment Naïve HIV-1 Subjects randomized to Atazanavir or Raltegravir or Darunavir plus Truvada Enrolling
Other NIH sponsored studies include:
Hearing Impairment in HIV/AIDS The study is enrolling 360 HIV +participants from the ID clinic who will have their hearing tested 6 times over a 4 year period. Enrolling

More Information

For more information, or to make an appointment, please contact us at
(585) 275-0526.